

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

A. FURTHER INFORMATION ABOUT OUR COMPANY

1. Incorporation of Our Company

Our Company was established as a limited liability company in the PRC on August 11, 2016, and was converted into a joint stock limited company on January 12, 2026 under the laws of the PRC. As of the Latest Practicable Date, the registered share capital of our Company was RMB17,715,951.

Our Company’s registered address is located at Room 302, Building 6, No.688, Bin An Road, Binjiang District, Hangzhou, China. Our Company’s corporate structure and Articles of Association are governed by PRC laws and regulations. The relevant PRC laws and regulations and a summary of the Articles of Association are set out in “Appendix III — Summary of the Articles of Association” to this document, respectively.

Our principal place of business in Hong Kong is at 46/F, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong. Our Company has been registered with the Registrar of Companies in Hong Kong as a non-Hong Kong company under Part 16 of the Companies Ordinance on February 20, 2026. Ms. Wong Mei Fung Carrie has been appointed as the authorized representative of our Company for the acceptance of service of process and notices on behalf of our Company in Hong Kong. The address for the service of process is the same as our principal place of business in Hong Kong.

2. Changes in the Share Capital of Our Company

Save as disclosed in “History, Development and Corporate Structure”, there has been no alteration in our share capital within the two years immediately preceding the date of publication of this document.

3. Changes in the Share Capital of Our Subsidiaries

A summary of the corporate information and the particulars of our subsidiaries are set out in Note 1 to the Accountants’ Report as set out in Appendix I to this document.

Save as disclosed below, there has been no alteration in the share capital of our subsidiaries during the two years immediately preceding the date of this document.

(1) Quzhou Jikang Medical Technology Co., Ltd. 衢州吉康醫療科技有限公司 (“Jikang Medical”)

On September 4, 2025, the share capital of Jikang Medical increased from RMB1,000,000 to RMB3,000,000.

On June 2, 2026, the share capital of Jikang Medical increased from RMB3,000,000 to RMB5,000,000.

4. Shareholders’ Resolutions

At the general meeting of our Company held on January 19, 2026, the following resolutions, among others, were passed by the Shareholders:

- (i) the issuance of H Shares with a nominal value of RMB0.10 each by our Company and such H Shares be [REDACTED] on the Stock Exchange;
- (ii) the number of H Shares to be issued pursuant to the [REDACTED] shall be no more than 25% of total issued share capital of our Company immediately following completion of the [REDACTED] (assuming that the [REDACTED] is not exercised), and the grant of the [REDACTED] in respect of no more than 15% of the number of H Shares issued pursuant to the [REDACTED];

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

- (iii) subject to the approval by the CSRC, upon completion of the [REDACTED], [REDACTED] Unlisted Shares in aggregate held by our Shareholders will be converted into H Shares on a one-for-one basis;
- (iv) subject to the completion of the [REDACTED], the conditional adoption of the Articles of Association, which shall become effective on the [REDACTED], and the Board has been authorized to amend the Articles of Association in accordance with any comments from the Stock Exchange and other relevant regulatory authorities; and
- (v) authorization of the Board and its authorized person to handle relevant matters relating to, among other things, the [REDACTED], the issue and listing of the H Shares.

5. Restrictions on Repurchase

See “Appendix III – Summary of the Articles of Association” for details.

B. FURTHER INFORMATION ABOUT OUR BUSINESS

1. Summary of Material Contracts

The following contracts (not being contract entered into in the ordinary course of business) have been entered into by members of our Group within the two years preceding the date of this document and are or may be material:

- (i) the [REDACTED]

2. Intellectual Property Rights

Trademarks

As of the Latest Practicable Date, we had registered the following trademarks which we consider to be or may be material to our business:

No.	Trademark	Place of Registration	Registered Owner	Class	Registration Number	Expiry Date
1	糖吉	PRC	The Company	1	60338051	April 27, 2032
2	糖吉	PRC	The Company	2	60350044	July 6, 2032
3	糖吉之家	PRC	The Company	3	22502229	February 13, 2028
4	糖吉	PRC	The Company	4	60346732	April 27, 2032
5		PRC	The Company	5	23291846	June 6, 2028

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

No.	Trademark	Place of Registration	Registered Owner	Class	Registration Number	Expiry Date
6	糖吉	PRC	The Company	5	23291668	September 20, 2028
7	TONGEE	PRC	The Company	5	42101497	February 27, 2031
8	糖吉之家	PRC	The Company	5	58433451	March 20, 2032
9	TONGEE	PRC	The Company	5	67060729	September 20, 2033
10	糖吉	PRC	The Company	5	67053252	March 27, 2033
11	Eshou	PRC	The Company	5	72847779	January 20, 2034
12	Endo-Gel	PRC	The Company	5	74295250	August 6, 2034
13	Endogel	PRC	The Company	5	74276783	August 27, 2034
14	Eshou	PRC	The Company	5	77857825	October 13, 2034
15	EShòu	PRC	The Company	5	78840712	November 13, 2034
16	Enjoy soul	PRC	The Company	5	80707190	March 13, 2035
17	JoyTrek	PRC	The Company	5	80711012	March 13, 2035
18	糖吉	PRC	The Company	6	60339888	April 27, 2032
19	糖吉	PRC	The Company	7	60348283	April 27, 2032
20	糖吉	PRC	The Company	8	60346790	April 27, 2032
21	康洛尼 KANG LUO NI	PRC	The Company	10	19256143	April 13, 2027
22	糖吉	PRC	The Company	10	23292145	March 13, 2028
23	TONGEE	PRC	The Company	10	23281130	October 13, 2028
24	糖吉之家	PRC	The Company	10	58440047	February 6, 2032

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

No.	Trademark	Place of Registration	Registered Owner	Class	Registration Number	Expiry Date
25		PRC	The Company	10	25224696	November 20, 2028
26	完美奥秘	PRC	The Company	10	40013148	April 6, 2030
27	糖吉	PRC	The Company	10	67058005	March 6, 2033
28		PRC	The Company	10	70612095	September 27, 2033
29	糖吉	PRC	The Company	13	60337714	April 27, 2032
30	糖吉	PRC	The Company	15	60351229	April 27, 2032
31	糖吉	PRC	The Company	16	60347170	April 27, 2032
32	糖吉	PRC	The Company	18	60347180	April 27, 2032
33	糖吉	PRC	The Company	22	60339091	April 27, 2032
34	糖吉	PRC	The Company	23	60343644	April 27, 2032
35	糖吉	PRC	The Company	25	60337748	April 27, 2032
36	糖吉	PRC	The Company	26	60337758	April 27, 2032
37	糖吉	PRC	The Company	27	60338093	April 27, 2032
38	糖吉	PRC	The Company	28	60345784	April 27, 2032
39	匀美	PRC	The Company	29	52118535	November 27, 2031
40		PRC	The Company	30	68454629	July 27, 2033
41	糖吉	PRC	The Company	32	60343258	July 6, 2032
42		PRC	The Company	37	68462801	August 13, 2033
43	吉享健康	PRC	Shanghai Tangji	9	78315915	January 6, 2035

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

No.	Trademark	Place of Registration	Registered Owner	Class	Registration Number	Expiry Date
44		PRC	Shanghai Tangji	9	82509420	August 6, 2035
45	吉享健康	PRC	Shanghai Tangji	10	78325397	July 6, 2035
46		PRC	Shanghai Tangji	44	82508347	July 20, 2035
47	吉享健康	PRC	Shanghai Tangji	44	78343508	September 27, 2035

Patents

As of the Latest Practicable Date, we had registered the following patents which we consider to be or may be material to our business:

No.	Patent number	Patent Name	Patent type	Holder	Jurisdiction	Patent Status	Date of Expiration
1	ZL201710499034.3	Gastric diverter and antibacterial digestive tract catheter thereof	Invention	Our Company	China	Granted	2037-06-27
2	EP3646827		Invention	Our Company	Europe	Granted	2037-10-13
3	IN478213		Invention	Our Company	India	Granted	2037-10-13
4	AU2017420550		Invention	Our Company	Australia	Granted	2037-10-13
5	JP6913825		Invention	Our Company	Japan	Granted	2037-10-13
6	RU2745080		Invention	Our Company	Russia	Granted	2037-10-13
7	ZL201810415050.4	Duodenum built-in jejunum cannula releasing system and a use method therefor	Invention	Our Company	China	Granted	2038-05-03
8	US12303466B2		Invention	Our Company	United States	Granted	2042-11-01
9	EP3789003		Invention	Our Company	Europe	Granted	2039-04-30
10	IN507039		Invention	Our Company	India	Granted	2039-04-30
11	CA3094114		Invention	Our Company	Canada	Granted	2039-04-30
12	RU2759594		Invention	Our Company	Russia	Granted	2039-04-30
13	MX422441		Invention	Our Company	Mexico	Granted	2039-04-30
14	BR112020019784-0		Invention	Our Company	Brazil	Granted	2039-04-30
15	ZL201810336514.2	Gastric diverter and release method thereof	Invention	Our Company	China	Granted	2038-04-12
16	ZL201810326731.3	Gastric diverter and digestive tract stent thereof	Invention	Our Company	China	Granted	2038-04-12
17	US11517461B2	Gastric diverter and digestive tract support and release method thereof	Invention	Our Company	United States	Granted	2039-03-21
18	EP3777784		Invention	Our Company	Europe	Granted	2038-10-24

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Patent number	Patent Name	Patent type	Holder	Jurisdiction	Patent Status	Date of Expiration
19	ZL201710293809.1	Intestinal barrier sleeve release system	Invention	Our Company	China	Granted	2037-04-28
20	US11622875B2		Invention	Our Company	United States	Granted	2038-10-29
21	EP3560463		Invention	Our Company	Europe	Granted	2037-06-28
22	IN485512		Invention	Our Company	India	Granted	2037-06-28
23	AU2017412054		Invention	Our Company	Australia	Granted	2037-06-28
24	JP6840270	Extendable digestive tract cannula and use thereof	Invention	Our Company	Japan	Granted	2037-06-28
25	RU2722311		Invention	Our Company	Russia	Granted	2037-06-28
26	ZL202311159684.5		Invention	Our Company	China	Granted	2043-09-08
27	TW1928771B	Digestive tract stent recovery device and endoscope cannula	Invention	Our Company	Taiwan Region	Granted	2045-05-14

As of the Latest Practicable Date, we had applied for the registration of the following patents which we consider to be or may be material to our business:

No.	Application number	Patent Name	Patent type	Holder	Jurisdiction	Patent Status	Date of Application
1	CN202410618308.6	Digestive tract stent recovery device and endoscope cannula	Invention	Our Company	China	Pending	2024-05-17
2	EP24938359.7		Invention	Our Company	Europe	Pending	2024-06-04
3	US19/528937		Invention	Our Company	United States	Pending	2024-06-04
4	PCT/CN2024/097364		Invention	Our Company	WIPO (PCT)	Pending	2024-06-04
5	CN202311152577.X	Release ball inner core for distal release of digestive tract cannula and preparation method and application thereof	Invention	Our Company	China	Pending	2023-09-07
6	US19/514389		Invention	Our Company	United States	Pending	2024-03-20
7	JP2026513734		Invention	Our Company	Japan	Pending	2024-03-20
8	CA3303552		Invention	Our Company	Canada	Pending	2024-03-20
9	EP24861465.3	Graded detachable digestive tract implant cannula and digestive tract implant kit	Invention	Our Company	Europe	Pending	2024-03-20
10	KR1020267006672		Invention	Our Company	South Korea	Pending	2024-03-20
11	CN202410126018.X		Invention	Our Company	China	Pending	2024-01-29
12	PCT/CN2024/083188		Invention	Our Company	WIPO (PCT)	Pending	2024-03-22
13	EP24921153.3	Automatic fracture type digestive tract cannula and kit	Invention	Our Company	Europe	Pending	2024-03-22
14	US19/528950		Invention	Our Company	United States	Pending	2024-03-22
15	CN202410125123.1		Invention	Our Company	China	Pending	2024-01-29
16	PCT/CN2024/082937		Invention	Our Company	WIPO (PCT)	Pending	2024-03-21
17	EP24921152.5	Extendable digestive tract cannula and use thereof	Invention	Our Company	Europe	Pending	2024-03-21
18	US19/528561		Invention	Our Company	United States	Pending	2024-03-21
19	US19/514787		Invention	Our Company	United States	Pending	2024-04-12
20	JP2026513949		Invention	Our Company	Japan	Pending	2024-04-12
21	EP24861493.5	Extendable digestive tract cannula and use thereof	Invention	Our Company	Europe	Pending	2024-04-12
22	KR1020267007507		Invention	Our Company	South Korea	Pending	2024-04-12

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

Save as disclosed above, as of the Latest Practicable Date, there were no other intellectual property rights that were material in relation to our business.

C. FURTHER INFORMATION ABOUT OUR DIRECTORS, CHIEF EXECUTIVE AND SUBSTANTIAL SHAREHOLDERS

1. Disclosure of Interests of Directors and Chief Executive

To the best knowledge of our Directors, save as disclosed below, immediately following the completion of the [REDACTED] (assuming (i) the [REDACTED] is not exercised and (ii) no other changes are made to the share capital of our Company between the Latest Practicable Date and the [REDACTED]), none of our Directors or chief executive has any interests or short positions in the Shares, underlying Shares and debentures of our Company or any associated corporations (within the meaning of Part XV of the SFO) which will have to be notified to our Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they are taken or deemed to have under such provisions of the SFO) or which will be required, pursuant to Section 352 of the SFO, to be recorded in the register referred to therein or which will be required to be notified to our Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Companies contained in the Listing Rules.

Interest in Shares of our Company

Name	Position	Shares to be held after the [REDACTED]	Nature of Interest	Number of Shares	Approximate % of the issued Shares immediately after the [REDACTED] ⁽¹⁾
Mr. Zuo	Chairman of the Board, executive Director and chief executive officer of our Company	H Shares	Beneficial owner; interest in controlled corporation	56,209,370 ⁽²⁾	[REDACTED]%
Dr. Xu Tianhong . .	Non-executive Director	H Shares	Beneficial owner	8,043,160	[REDACTED]%

Notes:

- (1) The calculation is based on the total number of [REDACTED] H Shares to be converted from Unlisted Shares in issue and [REDACTED] H Shares to be issued pursuant to the [REDACTED] (assuming that the [REDACTED] is not exercised).
- (2) As of the Latest Practicable Date, Mr. Zuo’s interest in our Company is composed of (i) 45,293,460 Shares directly held by Mr. Zuo; and (ii) 10,915,910 Shares held by Zhoushan Aizhong. Zhoushan Aizhong is a limited partnership established under the laws of the PRC, the general partner of which was Mr. Zuo. The partnership interests in Zhoushan Aizhong were held as to 12.64% by Mr. Zuo, who is the largest partner of Zhoushan Aizhong. For the purpose of the SFO, Mr. Zuo is deemed to be interested in the Shares held by Zhoushan Aizhong.

2. Interest of Substantial Shareholders

Interests in the Shares of our Company

Save as disclosed in the section headed “Substantial Shareholders” in this document, as of the Latest Practicable Date, our Directors were not aware of any persons who would, immediately following the completion of the [REDACTED] (assuming (i) the [REDACTED] is not exercised and (ii) no other changes are made to the issued share capital of our Company between the Latest Practicable Date and the [REDACTED]), having or be deemed or taken to the beneficial interests or short position in our Shares or

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

underlying Shares which would fall to be disclosed to our Company under the provisions of 2 and 3 of Part XV of the SFO, or directly or indirectly be interested in 10% or more of the issued voting shares of our Company or had option in respect of such capital.

Interests in our Company’s subsidiaries

As of the Latest Practicable Date, to the best knowledge of our Directors, other than members of our Group, none of the Directors or chief executive of our Company, or any other persons or entities was interested in 10% or more of the voting rights at general meetings of our subsidiaries.

3. Particulars of Service Contracts

Pursuant to Rules 19A.54 and 19A.55 of the Listing Rules, our Company [has entered into] a service agreement with each of the Directors which contains provisions in relation to, among other things, compliance of relevant laws and regulations, observations of Articles of Association and provisions on arbitration.

The principal particulars of these service agreements are: (a) each of the agreements is for a term of three years following his/her respective effective date of his/her appointment; and (b) each of the agreements is subject to termination in accordance with their respective terms. The service contracts can be renewed pursuant to our Articles of Association and applicable rules.

Save as disclosed above, our Company has not entered, and does not propose to enter, into any service contracts with any of the Directors in their respective capacities as Directors (other than contracts expiring or determinable by the employer within one year without the payment of compensation (other than statutory compensation)).

4. Directors’ remuneration

For details of the Directors’ remuneration, see “Directors and Senior Management — Remuneration of Directors and Senior Management” and Note 8 to the Accountants’ Report as set out in Appendix I to this document.

5. Disclaimers

Save as disclosed in this document,

- (a) none of our Directors or any of the parties listed in “Consents of Experts” of this Appendix is: has any interest or short position in the shares, underlying shares or debentures of our Company or any of its associated corporation (within the meaning of Part XV of the SFO) which will have to be notified to our Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO or which will be required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or which will be required to be notified to our Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers once the H Shares are listed;
- (b) none of our Directors or any of the parties listed in “— Other Information — 8. Consents of Experts” below:
 - (i) has any direct or indirect interest in the promotion of our Company, or in any assets which have within the two years immediately preceding the date of this document been acquired or disposed of by or leased to any member of our Group, or are proposed to be acquired or disposed of by or leased to any member of our Group;

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

- (ii) is materially interested in any contract or arrangement subsisting at the date of this document which is significant in relation to the business of our Group taken as a whole;
- (c) none of our Directors has any existing or proposed service contracts with any member of our Group (excluding contracts expiring or determinable by the employer within one year without payment of compensation (other than statutory compensation));
- (d) so far as is known to our Directors, no person (not being a Director of our Company or any member of our Group) will, immediately following the completion of the [REDACTED], have an interest or short position in the Shares or underlying Shares of our Company which would fall to be disclosed to our Company under the provisions of Divisions 2 and 3 of Part XV of SFO or be interested, directly or indirectly, in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of any member of our Group; and
- (e) none of our Directors or their respective close associates (as defined under the Listing Rules) or our Shareholders who are interested in more than 5% of the issued share capital of our Company has any interest in the five largest customers or the five largest suppliers of our Group.

6. Employee Incentive Scheme

In order to attract, retain and motivate key personnel, align the interests of the Company, its shareholders and employees, and support the Company’s long-term development strategy, the Company has implemented an employee equity incentive program in August 2019 (the “**Employee Incentive Scheme**”). To align with PRC practices for employee shareholding arrangements and to facilitate indirect holding of equity, our Employee Incentive Scheme is implemented through a PRC limited partnership shareholding platform Zhoushan Aizhong.

Under the Employee Incentive Scheme, eligible participants may be granted (i) performance-based incentive awards through Zhoushan Aizhong (including milestone options, key-position retention options and flexible bonus options) or (ii) restricted share grants priced by reference to the Company’s fair value (collectively, the “**Incentive Awards**”).

The Employee Incentive Scheme does not involve any grant of share options or awards after the [REDACTED] and therefore is not subject to the provisions of Chapter 17 of the Listing Rules. Given the underlying Shares under the Employee Incentive Scheme have already been issued, there will not be any further dilution effect to the issued Shares arising from the Share Incentive Scheme.

Below is a summary of the principal terms and provisions of the Employee Incentive Scheme.

Purpose

The Employee Incentive Scheme is designed to further enhance our corporate governance, establish a long-term incentive and restraint mechanism, strengthen corporate cohesion, uphold the direction of our long-term development and align the interests of our Company, its shareholders and employees, so as to attract, motivate and retain key management and technical personnel and support the realization of our strategic and operational goals.

Participants

The participants of the Employee Incentive Scheme include Directors, senior management, key employees of our Group (including the R&D department and other departments) and external consultants.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

Administration

The Employee Incentive Scheme is subject to the administration of the Board. The Board has authorized the Chairman of the Board, Mr. Zuo, to handle all matters related to the Employee Incentive Scheme, including but not limited to the formulation, revision and termination of the scheme.

Term

The Employee Incentive Scheme shall be valid and effective for 10 years from Board approval.

Lock-up and Vesting

The Shares underlying the interests granted to the participants are subject to lock-up and vesting conditions. The vesting conditions are categorized into three types:

- (i) 50% of the award vests upon the achievement of the Company’s annual performance targets;
- (ii) Vesting upon continuous service for not less than two years from the grant date or the [REDACTED] (whichever is later); or
- (iii) Vesting upon continuous service for not less than two years from the grant date and the successful [REDACTED] of the Company.

Repurchase and Clawback

The general partner of Zhoushan Aizhong (or a designated third party) has the right to repurchase the partnership interests from the participants under specific circumstances. If a participant engages in theft, fraud, violation of professional ethics, criminal behavior, breach of confidentiality/non-compete agreements, or actions detrimental to the Company’s reputation, the Company may repurchase their interests at the original cost.

If a participant resigns (without misconduct) or passes away or becomes incapacitated within four years of the grant, the unvested portion are repurchased at cost and the vested portion are repurchased at cost plus interest.

If a participant resigns (without misconduct) or passes away or becomes incapacitated after four years from the grant, unvested portions are repurchased at cost and vested portions are repurchased at cost plus interest.

Details of the Awards Granted Under the Employee Incentive Plan

As of the Latest Practicable Date, all Incentive Awards have been granted to the participants. The subscription price has been fully paid by the participants and the participants have become partners of Zhoushan Aizhong. The participants are entitled to the right to receiving dividends.

As of the Latest Practicable Date, the total number of Shares underlying the Incentive Awards was approximately 1,091,824, representing approximately 6.16% of the total issued Shares of our Company as of the Latest Practicable Date and approximately [REDACTED]% of the total issued Shares of our Company immediately after the [REDACTED].

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

The table below sets out the details of the Incentive Awards granted under the Employee Incentive Scheme as of the Latest Practicable Date:

<u>Name of the Participant</u>	<u>Position(s) in our Group</u>	<u>Approximate number of Shares corresponding to the partnership interests held by the Participant as of the Latest Practicable Date</u>	<u>Approximate shareholding percentage underlying the Awards granted to the Participant in the total number of the Shares in issue as of the Latest Practicable Date</u>	<u>Approximate shareholding percentage underlying the Awards granted to the Participant in the total number of the Shares in issue immediately after the [REDACTED]⁽¹⁾</u>
<i>Directors</i>				
Mr. Zuo	Chairman of the Board, executive Director and chief executive officer	138,008	0.78%	[REDACTED]%
<i>Senior management</i>				
Mr. Chen Jiahao	Chief marketing officer	108,740	0.61%	[REDACTED]%
Dr. Li Wenyu	Technical director	107,579	0.61%	[REDACTED]%
Mr. Wang Jingyu	Secretary to the Board	87,318	0.49%	[REDACTED]%
Ms. Yu Jiayan	Director of operation	74,904	0.42%	[REDACTED]%
Mr. Zhong Gaofeng	Director of clinical and registration affairs	68,014	0.38%	[REDACTED]%
Ms. Chen Junfei	Director of finance	55,652	0.31%	[REDACTED]%
<i>Other participants</i>				
37 employees and six external consultants	Employees and external consultants	451,609	2.55%	[REDACTED]%

Notes:

- The calculation is based on the assumption that no new Shares are issued under the [REDACTED] and no other changes are made to the issued share capital of our Company between the Latest Practicable Date and [REDACTED].

D. OTHER INFORMATION

1. Estate Duty

Our Directors have been advised that no material liability for estate duty is likely to fall on our Company or any of our subsidiaries.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

2. Litigation

As of the Latest Practicable Date, save as disclosed in this document, we were not aware of any litigation or arbitration proceedings of material importance pending or threatened against any member of our Group that could have a material adverse effect on our financial condition or results of operations.

3. Joint Sponsors’ Independence

The Joint Sponsors have made an application on behalf of our Company to the Listing Committee for the [REDACTED] of, and permission to deal in, our H Shares to be converted from Unlisted Shares and our H Shares to be issued pursuant to the [REDACTED]. All necessary arrangements have been made enabling the H Shares to be admitted into CCASS.

The Joint Sponsors satisfy the independence criteria applicable to sponsors as set out in Rule 3A.07 of the Listing Rules. The sponsors fee payable to the Joint Sponsors in connection with the [REDACTED] is approximately RMB4.4 million.

4. Compliance Adviser

Our Company has appointed Somerley Capital Limited as our Compliance Adviser in compliance with Rule 3A.19 of the Listing Rules.

5. Preliminary Expenses

As of the Latest Practicable Date, we have not incurred any material preliminary expenses in relation to the incorporation of our Company.

6. Taxation of Holder of H Shares

The sale, purchase and transfer of H Shares are subject to Hong Kong stamp duty if such sale, purchase and transfer are effected on the H Share register of members of our Company, including in circumstances where such transaction is effected on the Stock Exchange. The current rate of Hong Kong stamp duty for such sale, purchase and transfer is a 0.1% of the consideration or, if higher, the fair value of the H Shares being sold or transferred. For further information in relation to taxation, see “Regulatory Overview”.

7. Promoters

Within two years immediately preceding the date of this document, no cash, securities or other benefit has been paid, allotted or given nor is any proposed to be paid, allotted or given to any promoters in connection with the [REDACTED] and the related transactions described in this document.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

8. Consents of Experts

The following experts have each given and have not withdrawn their respective written consents to the issue of this document with copies of their reports, letters, opinions or summaries of opinions (as the case may be) and the references to their names included herein in the form and context in which they are respectively included.

Name	Qualification
ICBC International Capital Limited	Licensed to conduct type 1 (dealing in securities), type 4 (advising on securities), and type 6 (advising on corporate finance) regulated activities as defined under the SFO
Caitong International Capital Co., Limited . . .	Licensed to conduct type 1 (dealing in securities) and type 6 (advising on corporate finance) regulated activities as defined under the SFO
Ernst & Young	Certified Public Accountants under Professional Accountants Ordinance (Chapter 50 of the Laws of Hong Kong) and Registered Public Interest Entity Auditor under Accounting and Financial Reporting Council Ordinance (Chapter 588 of the Laws of Hong Kong)
Jingtian & Gongcheng	PRC Legal Advisors to our Company
Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.	Independent industry consultant

As of the Latest Practicable Date, save in connection with the [REDACTED], none of the experts named above had any shareholding interest in our Company or any of our subsidiaries or the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of our Group.

9. Bilingual Document

The English language and Chinese language versions of this document are being published separately in reliance upon the exemption provided by section 4 of the Companies (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).

10. Binding Effect

This document shall have the effect, if an application is made in pursuance of this document, of rendering all persons concerned bound by all of the provisions (other than the penal provisions) of Sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance in so far as applicable.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

11. No Material Adverse Change

Our Directors confirm that there has been no material adverse change in our financial, business position or prospects since June 30, 2026, being the end date of the periods reported on our consolidated financial statements as set out in the Accountants’ Report as set out in Appendix I to this document, and up to the date of this document.

Miscellaneous

Save as disclosed in this document:

- (i) within the two years immediately preceding the date of this document, to the best of our knowledge,
 - (a) neither our Company nor any of our subsidiaries has issued or agreed to issue any share or loan capital fully or partly paid up either for cash or for a consideration other than cash; and
 - (b) no commissions, discounts, brokerage fee or other special terms have been granted in connection with the issue or sale of any share or loan capital of our Company or any of our subsidiaries;
- (ii) there are no founder, management or deferred shares nor any debentures in our Company or any of our subsidiaries;
- (iii) no share or loan capital or debenture of our Company or any of the subsidiaries has been issued or agreed to be issued or is proposed to be issued for cash or as fully or partly paid otherwise than in cash;
- (iv) no share or loan capital or debenture of our Company or any of the subsidiaries is under option or is agreed conditionally or unconditionally to be put under option;
- (v) there are no arrangements under which future dividends are waived or agreed to be waived;
- (vi) there have been no interruptions in our business which may have or have had a significant effect on our financial position in the 12 months proceeding the date of this document; and
- (vii) our Company has no outstanding convertible debt securities or debentures.